|
|
Post by realisticview on Apr 10, 2014 13:23:51 GMT -5
|
|
|
|
Post by thekindaguyiyam on Apr 10, 2014 17:29:08 GMT -5
just replied to Adam:
"thekindaguyiyam • 2 minutes ago
You didn't mention if this insulin requires refrigeration? You think it's cool looking but to me it looks like it's 5X's larger than Mannkind's Dreamboat device for Afrezza. Likewise it seems to me that you are too early in trials to establish any competition as there success is a few years out. Meanwhile those waiting for long awaited relief look to the FDA to approve Afrezza to improve their lives NOW. What I have come to perceive you as is a voice for Short Sellers to use your slanted articles as smoke and mirrors during a Bear attack on the company Mannkind. Your blog article is superficial at best.
|
|
|
|
Post by thekindaguyiyam on Apr 11, 2014 1:19:56 GMT -5
Let's see. The Street publishes a second article; titled: One Factor Driving MannKind (MNKD) Stock Down TodaySurprising that they publish comments back to Adam. More of the same from those who want us to think that an upstart company can be compared to one that is being considered for near term distribution. With 63 million shorts it's laughable to think that they give merit to Adam's article for revealing the boogyman entity of Dance Biopharm. And now we have Adrew Meola giving credit to this two bit nub whabber. Who better to support a scumbag like adam than someone with no science background hired by the Street. Want to know if MNKD is in Cramers Porfolio? We already know. He has No Opinion.
BY Andrew Meola 04/10/14 - 02:40 PM EDT Find out if (MNKD) is in Cramer's Portfolio.NEW YORK (TheStreet) -- MannKind (MNKD_) dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled insulin device, Afrezza, has been the subject of much coverage recently with an FDA decision upcoming. An FDA advisory panel issued a positive recommendation on Afrezza last week. MannKind was down 4% to $6.72 at 2:39 p.m. For much more on Dance Biopharm, be sure to read TheStreet's Adam Feuerstein's article here. Must Read: MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO www.thestreet.com/story/12657820/1/one-factor-driving-mannkind-mnkd-stock-down-today.html?puc=yahoo&cm_ven=YAHOOWho is Andrew?"Andrew Meola This Author Andrew Meola joined TheStreet in January 2014 from The Hudson Valley Reporter, where he worked as the sports editor for Westchester, Putnam and Dutchess Counties. He previously worked at The Daily Voice, where he covered local news and sports in Westchester County. He is a proud graduate of Syracuse University's Newhouse School and is an avid New York sports fan and pop culture consumer. He once worked at a Steak-n-Shake for six hours." |
|
